Cite
HARVARD Citation
Eckstein, M. et al. (2019). Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. European journal of cancer. pp. 234-243. [Online].